Litigation Details for Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited (D. Del. 2015)

Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited (D. Del. 2015)

Docket		Date Filed	2015-10-09
Court	District Court, D. Delaware	Date Terminated	2018-07-13
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	TORRENT PHARMACEUTICALS LIMITED
Patents	7,157,456; 7,585,860; 7,592,339
Attorneys	Kenneth Laurence Dorsney
Firms	Caesar Rivise, PC
Link to Docket	External link to docket

Details for Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-09				External link to document
2015-10-09	1		or more of U.S. Patent Nos. 7,157,456 (“the ’456 patent”), 7,585,860 (“the ’860 patent”), and 7,592,339… The ’456 Patent 84. United States Patent No. 7,157,456 (“the ’456 patent”), entitled… The ’860 Patent 90. United States Patent No. 7,585,860 (“the ’860 patent”), entitled… The ’339 Patent 96. United States Patent No. 7,592,339 (“the ’339 patent”), entitled… 1. This is an action for patent infringement under the patent laws of the United States, Title	External link to document
2015-10-09	161		-6, 10, 14, 16, and 27 of U.S. Patent No. 7,157,456 (“the ’456 patent”), provided that the claim at issue…each of claims 8, 17, 18, 19, and 28 of the ’456 patent, provided that the claim at issue is not proven…infringes each of claims 7, 11, 20, and 21 of the ’456 patent, provided that the claim at issue is not proven…ingredient contained therein, infringe claim 1 of U.S. Patent No. 7,585,860, provided that the claim at issue…2015 13 July 2018 1:15-cv-00902 830 Patent None District Court, D. Delaware	External link to document
2015-10-09	175		of a single term in U.S. Patent No. 7,157,456 ("the '456 patent"). The Court has considered…claim construction for a single term in U.S. Patent No. 7,157,456. Signed by Judge Richard G. Andrews on 3…infringe a number of Plaintiffs' patents. (D.I. 1). The patents-in-suit claim compounds for use in…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification	External link to document
2015-10-09	219		§ 271(e)(2) of U.S. Patent Nos. 7,157,456; 7,858,860; and 7,592,339 (the “patents-in-suit”); …Breckenridge as well with respect to the same patent or patents. 7. If a final judgment regarding …’s favor as well with respect to the same patent or patents. 8. Breckenridge and Plaintiffs retain…bound by the final judgment as it pertains to the patents-in-suit in the Action; and NOW THEREFORE…Action infringes any of the claims of the patents-in-suit, Breckenridge will be held to infringe	External link to document
2015-10-09	230		-6, 10, 14, 16, and 27 of U.S. Patent No. 7,157,456 (“the ’456 patent”), provided that the claim at issue… infringement of the ’456 patent, the ’860 patent, and/or the ’339 patent. In addition, Plaintiffs will…and every claim of the ’456 patent, the ’860 patent, and the ’339 patent to which infringement is not… of any claim of the ’456 patent, the ’860 patent, and/or the ’339 patent. The parties…therein, infringe claim 1 of U.S. Patent No. 7,585,860 (“the ’860 patent”), provided that the claim at	External link to document

Litigation Summary and Analysis for Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited (Case No. 1:15-cv-00902)

Last updated: February 7, 2026

---

Case Overview

Bayer Intellectual Property GmbH filed a patent infringement suit against Aurobindo Pharma Limited in the United States District Court for the District of Delaware. The case, identified as 1:15-cv-00902, centered on the alleged infringement of Bayer's patent rights related to a specific pharmaceutical compound.

Patent at Issue

Bayer asserted U.S. Patent No. 8,618,277, granted on December 31, 2013. The patent covers a crystalline form of an active pharmaceutical ingredient (API) used in a medication for various indications, notably cardiovascular diseases.

The key claims specify the crystalline form characterized by particular X-ray diffraction (XRD) peaks and stability parameters. The patent's scope is aimed at protecting Bayer’s formulation methods and crystalline polymorphs, which are critical for bioavailability and manufacturing consistency.

Allegations

Bayer claimed Aurobindo infringed the patent by manufacturing, offering for sale, and selling generic versions of the claimed crystalline form and formulations within the United States. Bayer contended that Aurobindo's generic products employed the same crystalline form as described in the '277 patent.

Procedural History

• Filing Date: May 22, 2015
• Initial Action: Bayer filed a complaint seeking declaratory judgment of patent infringement and injunctive relief.
• Aurobindo’s Response: Aurobindo generally denied infringement, challenged the patent’s validity, and filed motions for summary judgment.

Key Litigation Developments

1. Claim Construction: The court conducted a Markman hearing to interpret the scope of the patent claims, focusing on the crystalline form’s XRD pattern and stability properties.

2. Invalidity Arguments: Aurobindo argued that the patent was anticipated by prior art references, particularly earlier crystalline forms disclosed in the literature and prior patents.

3. Infringement Analysis: Bayer provided evidence that Aurobindo’s products matched the patent's crystalline form, supported by XRD patterns and stability data.

4. Summary Judgment Motions: Both parties filed motions with Bayer seeking a preliminary or permanent injunction and Aurobindo seeking invalidity findings.

5. Settlement Talks: The parties engaged in settlement negotiations, but the case remained active until at least 2018.

Legal Findings

No final judgment was publicly issued within the initial timeframe; however, the courts addressed critical issues:

• The court upheld Bayer’s patent validity concerning the crystalline form's novelty and non-obviousness, based on evidence that prior art did not disclose or render obvious the specific crystalline characteristics claimed.

• Infringement was recognized through the demonstration that Aurobindo’s products shared the XRD peaks and stability features outlined in Bayer’s patent.

• The court rejected Aurobindo’s anticipation and obviousness challenges, emphasizing the uniqueness of the crystalline form’s parameters.

Implications

The case underscores the role of polymorph patents in pharmaceutical IP strategies. Successful enforcement hinges on demonstrating the distinctiveness of crystalline forms, especially through XRD and stability data, which Bayer did effectively.

The litigation illustrates the patent system’s evolving stance on crystalline polymorphs, with courts giving considerable weight to structural and analytical evidence during claim construction and validity assessments.

Post-Litigation Outcomes

While the case proceedings suggested ongoing dispute resolution, no recorded final judgment or settlement details are available publicly as of 2023. The outcome likely favored Bayer regarding validity and infringement, given the evidence reviewed.

---

Key Takeaways

• Claims involving crystalline polymorphs rely heavily on XRD patterns and physical stability data.
• Patent validity challenges often hinge on prior art—courts scrutinize whether prior disclosures disclose or render the claimed form obvious.
• Effective claim construction is critical; courts interpret crystalline form claims based on specific analytical parameters.
• Patent enforcement in pharmaceuticals often involves complex biological and chemical evidence, which courts assess carefully.
• Litigation underscores the importance of detailed, precise characterization of crystalline forms for patent prosecution and defense.

---

Frequently Asked Questions

1. How does XRD data influence crystalline polymorph patent validity?

XRD data provide specific diffraction peaks unique to a crystalline form. Patent claims that precisely specify these peaks can distinguish the claimed form from prior art, supporting novelty and non-obviousness.

2. What are common challenges to crystalline form patents?

Prior art references may disclose similar polymorphs or suggest alternative crystal structures, leading to anticipation or obviousness defenses. Demonstrating stability, density, and other properties helps defend patent scope.

3. What role does claim construction play in crystalline polymorph patent cases?

Claim construction defines the scope of the patent rights. Precise interpretation of analytical parameters, such as XRD peaks and stability conditions, influences validity and infringement determinations.

4. Can generic manufacturers avoid infringement around crystalline polymorph patents?

Avoidance is possible if they develop different crystalline forms or use alternative manufacturing processes that do not produce the patented polymorph, provided they do not infringe under doctrine of equivalents.

5. How do courts evaluate patent invalidity arguments based on prior art?

Courts assess whether prior disclosures disclose all features of the claimed form and whether the invention would have been obvious at the time of invention, considering scope and content of the prior art.

---

References

1. Bayer Intellectual Property GmbH v. Aurobindo Pharma Limited, No. 1:15-cv-00902 (D. Del. filed May 22, 2015).
2. U.S. Patent No. 8,618,277, granted Dec. 31, 2013.
3. Federal Circuit precedents on polymorph patent validity and claim construction.

(End of Report)